Using red blood cells as therapeutics: Flagship Ventures launches Rubius Therapeutics with $25M
The company plans to enter the clinic by the close of 2016 with a red blood cell-based therapy that treats phenylketonuria.
The company plans to enter the clinic by the close of 2016 with a red blood cell-based therapy that treats phenylketonuria.